Acute Myocardial Infarction | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

Background: Extracorporeal membrane oxygenation (ECMO) offers therapeutic options in
refractory respiratory and/or cardiac failure. Systemic anticoagulation with heparin is …

Background The comparative efficacy of various anticoagulation strategies has not been
clearly established in patients with acute myocardial infarction who are undergoing …

Inflammation and thrombosis occur together in many diseases. The leukocyte integrin Mac-1
(also known as integrin αMβ2, or CD11b/CD18) is crucial for leukocyte recruitment to the …

A Cardiologia Intervencionista tem experimentado extraordinário avanço nos últimos anos,
sendo atualmente o método de revascularização do miocárdio mais empregado em todos …

Antithrombotic therapy, including antiplatelet and anticoagulant agents, is the cornerstone of
pharmacological treatment to optimize clinical outcomes in patients with ST-segment …

Argatroban and bivalirudin are parenteral direct inhibitors of the activity of thrombin, but,
unlike heparin, can inhibit both soluble as well as clot-bound thrombin. These agents do not …

Background: The risk of recurrent ischemic and bleeding events after primary percutaneous
coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) may not …

Despite a large volume of evidence supporting the use of dual antiplatelet therapy in
patients with acute coronary syndrome, there remains major uncertainty regarding the …

Background Evaluation of antithrombotic treatments for acute coronary syndromes (ACS)
requires balancing ischemic and bleeding risks to assess net benefit. We sought to compare …